{"id":134033,"date":"2026-06-29T13:32:22","date_gmt":"2026-06-29T08:02:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=134033"},"modified":"2026-06-29T13:32:23","modified_gmt":"2026-06-29T08:02:23","slug":"dr-reddys-share-price-extend-rise-6th-day-52week-high","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-extend-rise-6th-day-52week-high\/","title":{"rendered":"Dr Reddy’s Laboratories Shares Extend Rise for 6th Day to Hit 52-Week High on High Volumes"},"content":{"rendered":"
<\/div>\n

DRREDDY Rs 1,376.60 (+1.93%). 52W High Rs 1,414.90 set today intraday. 52W Low Rs 1,148.40. 6th consecutive gain. Nifty Pharma +1.73%. USFDA Form 483 – 7 obs, Bachupally. Vol 4M+.<\/em><\/p>\n

Dr Reddy’s<\/a> share price has risen for the sixth consecutive trading session, touching a new 52-week high of Rs 1,414.90 intraday before settling around Rs 1,376.60, still up 1.93% from the previous close of Rs 1,350.50. The six-day winning streak has established a fresh annual high, surpassing the previous 52-week high of Rs 1,375.90 during the day’s session, on trading volumes exceeding 4 million shares. The rally comes even as the USFDA issued a Form 483 with seven observations at Dr Reddy’s biologics manufacturing facility in Bachupally, Hyderabad, following a Pre-License Inspection conducted between June 16 and June 25. Investors are treating the observation report as a standard regulatory interaction rather than a material compliance risk, contributing to the continued strength in the Dr Reddy’s share price.<\/p>\n

The Nifty Pharma index is the top performing sector today at +1.73% to 25,402, providing strong sectoral tailwinds to Dr Reddy’s. The Indian Pharmaceutical Market recorded 12.1% year-on-year growth in May 2026, its sixth consecutive month of double-digit domestic IPM expansion, driven simultaneously by volume, pricing and new product introduction. Nomura has a Buy rating on Dr Reddy’s with a target price of Rs 1,740, citing the company’s strategic shift toward branded generics and biosimilar pipeline as re-rating catalysts.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n